Literature DB >> 1894193

Thrombin inhibition by hirudin: how hirudin inhibits thrombin.

J W Fenton1, G B Villanueva, F A Ofosu, J M Maraganore.   

Abstract

In addition to its classical active-site regions (catalytic site and adjacent regions), alpha-thrombin has a unique anion-binding exosite, which is functionally independent of the catalytic site and is involved in fibrin(ogen) recognition. This exosite also accounts for adhesion to negatively charged surfaces (e.g., glass), binding to cell surfaces, and interactions with the anionic tail of hirudin. Hirudin (as an apolar, tridisulfide-linked core structure followed by its anionic tail) interacts with alpha-thrombin by apolar (e.g., catalytic-site and adjacent regions of thrombin), as well as by ionic binding (e.g., anion-binding exosite). Circular dichroism measurements reveal a sigmoidal nonadditivity for the hirudin tail fragments, which block fibrinogen-clotting activity without interfering with tripeptide chromogenic substrate activities. Such fragments, however, inhibit factor V activation to much lesser extents than hirudin, where factor V activation is the key step in regulating thrombin generation by hirudin or heparin/antithrombin III. Hirudin-derived antithrombotics may thus have differential modes of action in hemostasis and wound healing processes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1894193     DOI: 10.1159/000216259

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  13 in total

1.  Comparison of two different ecarin clotting time methods.

Authors:  Tivadar Fenyvesi; Job Harenberg; Christel Weiss; Ingrid Jörg
Journal:  J Thromb Thrombolysis       Date:  2005-08       Impact factor: 2.300

2.  Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.

Authors:  I V Smirnova; S Vamos; T Wiegmann; B A Citron; P M Arnold; B W Festoff
Journal:  J Mol Neurosci       Date:  1998-02       Impact factor: 3.444

3.  Oxidative folding of hirudin in human serum.

Authors:  Jui-Yoa Chang; Bao-Yun Lu; Por-Hsiung Lai
Journal:  Biochem J       Date:  2006-02-15       Impact factor: 3.857

Review 4.  Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.

Authors:  K W Mahaffey
Journal:  Curr Cardiol Rep       Date:  2001-09       Impact factor: 2.931

5.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

6.  Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.

Authors:  C A McNamara; I J Sarembock; L W Gimple; J W Fenton; S R Coughlin; G K Owens
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

Review 7.  The characteristics of thrombin in osteoarthritic pathogenesis and treatment.

Authors:  Pei-Yu Chou; Chen-Ming Su; Chun-Yin Huang; Chih-Hsin Tang
Journal:  Biomed Res Int       Date:  2014-09-16       Impact factor: 3.411

Review 8.  Antiviral anticoagulation.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Bryan H Lin; Marc Horwitz
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

9.  The hirudin-like factors HLF3 and HLF4-hidden hirudins of European medicinal leeches.

Authors:  Christian Müller; Phil Lukas; Dana Sponholz; Jan-Peter Hildebrandt
Journal:  Parasitol Res       Date:  2020-05-04       Impact factor: 2.289

10.  Screening of the Promising Direct Thrombin Inhibitors from Haematophagous Organisms. Part I: Recombinant Analogues and Their Antithrombotic Activity In Vitro.

Authors:  Maria A Kostromina; Elena A Tukhovskaya; Elvira R Shaykhutdinova; Gulsara A Slashcheva; Alina M Ismailova; Victor A Palikov; Yuliya A Palikova; Igor A Dyachenko; Irina N Kravchenko; Elena S Sadovnikova; Nadezhda I Novikova; Natalia A Perepechenova; Evgeniy A Zayats; Yuliya A Abramchik; Dmitry D Lykoshin; Andrey N Mamaev; Elena V Grigorieva; Andrey P Momot; Arkady N Murashev; Roman S Esipov
Journal:  Biomedicines       Date:  2021-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.